Cervical Cancer

Cervical cancer prevention and early detection depend on validated high-risk HPV testing, cytology-based triage when indicated, and reliable completion of colposcopy and treatment pathways. High-risk HPV infection is considered necessary for virtually all cervical cancers; FDA guidance identifies 12 carcinogenic genotypes as core targets for high-risk HPV assays: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59. fdafdaEstablishing the Performance Characteristics of In Vitro ...

Once invasive cancer is diagnosed, management is stage- and resectability-dependent and should be coordinated with gynecologic oncology and radiation oncology. Available evidence supports surgery or radiation-based treatment for localized disease, while concurrent chemoradiation is used for locally advanced disease; brachytherapy remains a critical component of definitive radiation treatment. ScienceDirect+1ScienceDirectUpdated Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States: A Surveillance, Epidemiology, and End-Results Study - ScienceDirectScienceDirectCurrent treatment options and limitations for cervical cancer - ScienceDirect

For persistent, recurrent, or metastatic disease, treatment selection is driven by prior therapy, performance status, organ function, disease distribution, and tumor biomarkers—particularly PD-L1 expression for pembrolizumab eligibility in the FDA-approved first-line setting. fdafdaFDA approves pembrolizumab combination for the first-line treatment of cervical cancer | FDA

The supplied evidence supports three broad screening modalities: cytology alone, high-risk HPV testing alone, and cotesting. In a network meta-analysis of 27 prospective studies involving 185,269 asymptomatic women, non-HPV16/18 high-risk HPV assays were generally more sensitive and less specific for CIN2+ than standalone cytology. NatureNatureComparative accuracy of cervical cancer screening strategies in healthy asymptomatic women: a systematic review and network meta-analysis | Scientific Reports

Combining cytology and high-risk HPV testing increases or decreases sensitivity and specificity according to the rule used. An either-positive rule maximizes sensitivity at the expense of specificity, whereas requiring both tests to be positive increases specificity but lowers sensitivity. This tradeoff matters because false-positive screening tests lead to additional testing, colposcopy, biopsy, and potential overtreatment. NatureNatureComparative accuracy of cervical cancer screening strategies in healthy asymptomatic women: a systematic review and network meta-analysis | Scientific Reports

FDA device guidance emphasizes that clinical validity is tied to the specific intended use, population, specimen type, collection medium, and assay cutoff. A negative result does not validate an assay outside its approved specimen and clinical-use setting. False-negative results can delay diagnosis, whereas false-positive results can lead to unnecessary colposcopy, biopsy, and potentially fertility-affecting treatment. fdafdaEstablishing the Performance Characteristics of In Vitro ...

Colposcopy with biopsy, when indicated, provides the clinical reference standard for assessment of cervical precancer and cancer in HPV device studies. FDA guidance recommends standardized biopsy methods, blinded assessment of investigational HPV results, and pathology reporting that distinguishes CIN2 from CIN3 because CIN3 is more likely to progress to cancer. fdafdaEstablishing the Performance Characteristics of In Vitro ...

For women with ASC-US cytology undergoing HPV triage, FDA guidance describes prospective evaluation in which all women proceed to colposcopy irrespective of HPV status, with colposcopy performed within 12 weeks of the screening specimen. This design avoids verification bias in test assessment; in practice, management should follow current risk-based U.S. guidance rather than the device-study protocol alone. fdafdaEstablishing the Performance Characteristics of In Vitro ...

A negative HPV result should not prevent colposcopy when cytology is more severe than ASC-US. FDA specifically notes that, in women aged 30 years or older with greater than ASC-US cytology, a negative HPV result should not prevent referral to colposcopy. fdafdaEstablishing the Performance Characteristics of In Vitro ...

The supplied sources support surgery and radiation as principal modalities for localized cervical cancer, with concurrent chemoradiation described as the treatment of choice for locally advanced tumors. ScienceDirectScienceDirectCurrent treatment options and limitations for cervical cancer - ScienceDirect Selection between surgery and radiation depends on disease extent, anticipated need for adjuvant treatment, patient comorbidity, and fertility implications; detailed stage-specific operative criteria are not available in the supplied sources.

For stage IB2–IVA cervical cancer, brachytherapy utilization is independently associated with lower cervical cancer-specific mortality and all-cause mortality in U.S. observational analyses. The source characterizes brachytherapy as an essential component of treatment for locally advanced cervical cancer. ScienceDirectScienceDirectUpdated Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States: A Surveillance, Epidemiology, and End-Results Study - ScienceDirect

The practical implication is referral early enough to avoid substituting external-beam dose escalation for an indicated brachytherapy boost. MRI-guided brachytherapy has been associated with an approximately 10% overall-survival benefit compared with historical cohorts in the evidence summarized by the SEER analysis, but that estimate is not from a randomized comparison. ScienceDirectScienceDirectUpdated Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States: A Surveillance, Epidemiology, and End-Results Study - ScienceDirect

For persistent, recurrent, or metastatic cervical cancer with tumor PD-L1 CPS of at least 1, the FDA approved pembrolizumab in combination with chemotherapy, with or without bevacizumab, as first-line treatment. In the FDA-reviewed trial population with CPS at least 1, median overall survival was not reached with pembrolizumab-based therapy versus 16.3 months with placebo-based therapy (hazard ratio 0.64); median progression-free survival was 10.4 versus 8.2 months (hazard ratio 0.62). fdafdaFDA approves pembrolizumab combination for the first-line treatment of cervical cancer | FDA

Tisotumab vedotin-tftv received FDA accelerated approval for adults with recurrent or metastatic cervical cancer progressing on or after chemotherapy. In a single-arm study of 101 patients treated with 2 mg/kg intravenously every 3 weeks, confirmed objective response rate was 24% and median response duration was 8.3 months. Labeling included a boxed warning for ocular toxicity. fdafdaFDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer | FDA

Topotecan plus cisplatin remains FDA-labeled for stage IVB, recurrent, or persistent cervical carcinoma not amenable to curative surgery or radiation. The labeled regimen is topotecan 0.75 mg/m² IV over 30 minutes on days 1–3 plus cisplatin 50 mg/m² IV on day 1 every 21 days. In the cited comparative trial, median survival was 9.4 months with the combination versus 6.5 months with cisplatin alone. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use TOPOTECAN INJECTION safely and effectively. See full prescribing information for TOPOTECAN INJECTION. TOPOTECAN Injection Must be diluted before intravenous infusion Initial U.S. Approval: 1996

Urine-based HPV and methylation strategies are promising, especially for reaching underscreened populations, but the cited clinical study was performed in European referral and control cohorts rather than a U.S. population screening program. It explicitly identifies the need for longitudinal validation to define safe screening intervals. NatureNatureClinical performance of ASCL1/LHX8 DNA methylation on first-void urine to screen for cervical cancer | Communications Medicine

Machine-learning studies using small public datasets should not guide clinical diagnosis or replace validated screening and diagnostic pathways. One cited model achieved near-perfect performance using a dataset of 858 records, but the model incorporated Schiller, Hinselmann, cytology, and biopsy-related testing variables; these are not independent pre-screening risk factors and create a high risk of circular prediction rather than clinically transportable diagnostic performance. NatureNatureEnhanced cervical cancer diagnosis using a novel Bayesian fusion ensemble method with explainable AI | Scientific Reports

For screening and triage, use patient-important outcomes—not only cross-sectional test accuracy—to assess benefit. The network meta-analysis concludes that comparative strategies need evaluation at the program level, including false-positive procedures, false negatives, long-term outcomes, resources, and costs. NatureNatureComparative accuracy of cervical cancer screening strategies in healthy asymptomatic women: a systematic review and network meta-analysis | Scientific Reports